# Phase II Study of Reuse of Oxaliplatin Hypersensitivity in Gastrointestinal Tumors

> **NCT05922358** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fujian Cancer Hospital** · enrollment: 500 (estimated)

## Conditions studied

- Gastrointestinal Tumors

## Interventions

- **COMBINATION_PRODUCT:** Anti-allergic treatment

## Key facts

- **NCT ID:** NCT05922358
- **Lead sponsor:** Fujian Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-09-01
- **Primary completion:** 2025-09-01
- **Final completion:** 2026-09-01
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2023-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05922358

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05922358, "Phase II Study of Reuse of Oxaliplatin Hypersensitivity in Gastrointestinal Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05922358. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*